The Federal Service for Surveillance in Healthcare (Roszdravnadzor) reports that in the first eight months of 2024, prices for vital and essential medications (VED) rose by a modest 4.6% at most. This is below the inflation rate and corresponds to the growth rates of previous years, said the head of the agency, Alla Samoilova, during parliamentary hearings of the State Duma Committee on Health Protection, dedicated to the topic of “Drug Safety in the Russian Federation”.
“This is lower than inflation, and approximately in the same numbers as in previous years, that is, for similar periods of previous years,” she said, also noting that 100% of the turnover of drugs is controlled by the digital labeling system.
